Chemed (NYSE:CHE) CEO Kevin Mcnamara Sells 2,000 Shares of Company Stock

Chemed Corporation (NYSE:CHE) CEO Kevin Mcnamara sold 2,000 shares of the company’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the sale, the chief executive officer directly owned 66,418 shares of the company’s stock, valued at $34,102,322.10. The trade was a 2.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Chemed Price Performance

CHE traded down $6.28 on Wednesday, reaching $505.77. 69,772 shares of the company’s stock were exchanged, compared to its average volume of 207,573. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $557.00. The stock has a market cap of $6.61 billion, a PE ratio of 25.42, a P/E/G ratio of 2.07 and a beta of 0.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. The stock’s fifty day moving average price is $523.47 and its 200-day moving average price is $460.53.

Chemed (NYSE:CHE) last issued its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, topping the consensus estimate of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The business had revenue of $673.25 million for the quarter, compared to analysts’ expectations of $665.04 million. During the same period in the previous year, the firm posted $4.27 EPS. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Sell-side analysts expect that Chemed Corporation will post 23.55 EPS for the current year.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were issued a dividend of $0.70 per share. The ex-dividend date was Monday, August 17th. This represents a $2.80 annualized dividend and a dividend yield of 0.6%. This is a boost from Chemed’s previous quarterly dividend of $0.60. Chemed’s payout ratio is presently 14.06%.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. UBS Group began coverage on shares of Chemed in a research report on Friday, September 25th. They set a “buy” rating and a $650.00 price target on the stock. Oppenheimer upped their target price on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Royal Bank Of Canada raised their price target on shares of Chemed from $436.00 to $548.00 and gave the company a “sector perform” rating in a research report on Thursday, July 30th. Bank of America restated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Finally, Weiss Ratings raised Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $554.60.

Institutional Trading of Chemed

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Sequoia Financial Advisors LLC purchased a new stake in shares of Chemed in the 2nd quarter valued at $563,000. Integrated Wealth Concepts LLC grew its holdings in Chemed by 9.7% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 27,774 shares of the company’s stock worth $12,936,000 after acquiring an additional 2,461 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Chemed by 4,167.3% during the 2nd quarter. NewEdge Advisors LLC now owns 2,091 shares of the company’s stock worth $974,000 after purchasing an additional 2,042 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Chemed by 50.5% in the second quarter. Squarepoint Ops LLC now owns 5,201 shares of the company’s stock valued at $2,422,000 after buying an additional 1,745 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its holdings in Chemed by 28.8% during the 2nd quarter. Baird Financial Group Inc. now owns 1,874 shares of the company’s stock worth $873,000 after buying an additional 419 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

About Chemed

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.